Why Your Saliva Kit Isn’t Enough: The Truth About Direct-to-Consumer Genetic Testing

At-home genetic tests are becoming more prevalent in the market; however, not all tests are created equally. Assuming what they can do may leave patients frustrated when they don't receive the intended results.

With just a quick spit in a tube and a few clicks online, millions of people believe they’ve unlocked the secrets of their DNA. Direct-to-consumer (DTC) genetic tests like 23andMe, AncestryDNA, and others promise to deliver deep insights into your ancestry, traits, and even your disease risk. Clinics and health centers – especially those with limited resources – sometimes use these kits as a stand-in for comprehensive genetic screening. But while these services can provide interesting information, they do not offer clinical-grade data.

This misunderstanding is not just a technical one; it has real consequences. Patients make decisions about their health based on incomplete reports. Providers may miss actionable insights because they trust an over-the-counter product. At Phronetik, we’ve seen how DTC misunderstandings widen gaps in care, particularly in communities that can’t afford to make costly mistakes. That’s why we’re committed to breaking down these myths and showing exactly why a clinical-grade approach is essential and how Phronetik ensures it's accessible to all.

What People Think: “The Spit Test Tells Me Everything”

It’s understandable why people think this way. DTC companies advertise compelling benefits:

• Discover your risk for over 100 conditions

• Get insights into medication responses

• Learn your ancestry breakdown in minutes

• Receive personalized reports straight to your inbox

Many patients, even some providers, assume this means they’ve gotten a comprehensive, medical-grade genomic analysis. They believe that these kits screen for all major genetic risks, use the same technology as hospitals, and can be used to make informed medical decisions. The sleek dashboards and health flags make it feel official.

In many Federally Qualified Health Centers (FQHCs), patients bring in their DTC results as if they were lab reports. They ask whether they should be worried about the diseases mentioned on the summary page. Some providers and Minority-Serving Institutions (MSIs) looking to start research programs assume that DTC tests provide an adequate baseline to launch community genomic studies.

Unfortunately, this perception is both widespread and dangerously flawed.

Why That’s Incorrect: The Limitations of Consumer Genetic Testing

1. Limited Genotyping, Not Full Sequencing

DTC companies typically use SNP genotyping, which scans for several hundred thousand known variants. That might sound like a lot until you consider that the human genome has over 3 billion base pairs and millions of variants. DTC tests miss:

• Rare variants that are not commonly found in general populations

• Structural variants (like deletions or insertions)

• Copy number variants, which are common in cancer, neurological, and cardiovascular conditions

• Gene fusions, relevant in oncology and personalized therapy

In contrast, clinical-grade testing uses Next-Generation Sequencing (NGS), including whole-exome sequencing (WES) or targeted panels that deeply analyze regions where medically significant variants are most likely to occur.

2. No Clinical Context or Interpretation

DTC health reports are not interpreted using clinical-grade standards. They typically do not adhere to ACMG guidelines, don’t assess variant pathogenicity rigorously, and don’t factor in family history, lifestyle, or co-morbidities. More concerning, these reports often flag minor risks that aren’t clinically meaningful while missing critical, actionable variants.

For example, someone might be told they have an increased risk of macular degeneration, but they may not be screened for conditions like Lynch Syndrome, BRCA1/2 mutations, or familial hypercholesterolemia, which have major treatment implications.

3. Lack of Diversity in Reference Panels

Most DTC tests are built on reference genomes from individuals of European descent. This leads to:

• High false negative rates for African American, Latino, Asian, and Indigenous populations

• Variants of unknown significance (VUS) are more frequent in non-white populations

• Inaccurate carrier status interpretations in diverse communities

 The bottom line? DTC tests are not designed to diagnose, guide treatment, or assess risk across diverse populations in a clinically meaningful way.

4. No Clinical Support or Follow-up

If your DTC test says you’re at elevated risk for Parkinson’s, what happens next? Who walks you through what that means? Who helps you get a neurologist? There’s no genetic counselor on the other side of a DTC email. Without professional support, these reports can create undue anxiety or false reassurance.

What the Correct Understanding Should Be

Patients should consult with their physician to understand the benefits & use cases of genetic testing.

1. Clinical-Grade Testing Is the Gold Standard

A true medical-grade genomic test must be conducted in a CLIA-certified, CAP-accredited laboratory using high-depth NGS. It should:

• Sequence the whole exome (protein-coding regions) or a targeted clinical panel

• Deliver variant interpretation according to ACMG guidelines

• Include ancestry-aware, population-specific reference data

• Provide a clinical report reviewed by qualified geneticists and physicians

2. Ancestry and Clinical Context Matter

A variant that’s pathogenic in one population may be benign in another. For communities served by FQHCs and MSIs – often underrepresented in genomic studies – DTC tests may entirely miss relevant findings. Clinical-grade testing includes variant reclassification protocols, updates from public databases, and advanced tools for population-specific insights.

3. DTC Can Be a Starting Point, But Never the Finish Line

Think of DTC testing like a selfie; it gives you a surface-level snapshot. Clinical-grade testing is like a 3D MRI – a comprehensive, layered view that integrates DNA, health history, and real-world outcomes. DTC can pique interest, but it should always be followed up with a validated clinical pathway.

How Phronetik Does It Right: Our Clinical-Grade, Equity-Focused Model

1. We Operate Our Own CLIA-Certified Genomics Laboratory

Phronetik doesn’t outsource our testing. We built and run our own CLIA-certified lab, which allows us to:

• Conduct high-quality NGS in-house (WES, targeted panels, and WGS as needed)

• Maintain full control of quality assurance, turnaround time, and data security

• Ensure that every test is interpreted and reported by clinical genetics experts

This is especially important for community clinics and MSI partners who need real, actionable data to improve outcomes, inform care plans, or support grant-funded research.

2. We Contextualize Genomic Data with Population-Specific Insight

Because Phronetik works closely with FQHCs and MSIs, we don’t use generic reference data. We incorporate ancestry-aware variant interpretation and maintain partnerships with researchers building representative databases. This ensures:

• Lower VUS rates in African American, Hispanic, and Indigenous patients

• More accurate carrier screening in diverse communities

• Clinical guidance tailored to each population’s needs

3. We Provide Follow-Up, Counseling, and Community Integration

Our process doesn’t end with a report. Phronetik provides:

• Genetic counseling for patients

• Education and training for FQHC and MSI clinical staff

• Culturally competent support materials for families

• Integration with local services and specialists for the next steps

In short, we close the loop between data and care, ensuring that what we find leads to what’s needed.

Final Thoughts: Know More, Do Better

Your DNA is one of the most powerful tools you have, but only if it’s interpreted correctly, in the right context, and with your community in mind. Direct-to-consumer testing is convenient, but it is not comprehensive, not clinical, and not equitable for many underserved populations.

At Phronetik, we believe every person, regardless of zip code, background, or income, deserves access to precision health done right. That begins with understanding the limitations of DTC testing and selecting a partner that prioritizes clinical excellence, equity, and community impact.

Call to Action

For Patients & Families: Ready to go beyond the spit kit? Schedule your clinical-grade genomic consultation with Phronetik today: Book an Appointment

For Clinics & FQHCs: Want to replace DTC myths with medically valid reports? Learn how to integrate Phronetik into your care model: Partner with Us

For MSI Researchers: Thinking of building a genomics program? Don’t start with DTC – co-author your next grant with us and build it right: MSI Lab Development

Stay tuned for our next post, “Next-Generation Sequencing Is Too Expensive for Community Clinics or Small Universities,” and subscribe to our newsletter for deeper insights into building a healthier, more equitable future.

Join the conversation. Follow us on LinkedIn & Facebook, and subscribe to our Newsletter for updates on how we’re transforming healthcare for all.

Passion + Perseverance = Phronetik Progress. 

We ARE Precision Medicine